<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34318620</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Humoral response to neurofilaments and dipeptide repeats in ALS progression.</ArticleTitle><Pagination><StartPage>1831</StartPage><EndPage>1844</EndPage><MedlinePgn>1831-1844</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51428</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To appraise the utility as biomarkers of blood antibodies and immune complexes to neurofilaments and dipeptide repeat proteins, the products of translation of the most common genetic mutation in amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="METHODS">Antibodies and immune complexes against neurofilament light, medium, heavy chains as well as poly-(GP)-(GR) dipeptide repeats were measured in blood samples from the ALS Biomarkers (n&#xa0;=&#xa0;107) and the phenotype-genotype biomarker (n&#xa0;=&#xa0;129) studies and in 140 healthy controls. Target analyte levels were studied longitudinally in 37 ALS cases. Participants were stratified according to the rate of disease progression estimated before and after baseline and C9orf72 genetic status. Survival and longitudinal analyses were undertaken with reference to matched neurofilament protein expression.</AbstractText><AbstractText Label="RESULTS">Compared to healthy controls, total neurofilament proteins and antibodies, neurofilament light immune complexes (p&#xa0;&lt;&#xa0;0.0001), and neurofilament heavy antibodies (p&#xa0;=&#xa0;0.0061) were significantly elevated in ALS, patients with faster progressing disease (p&#xa0;&lt;&#xa0;0.0001) and in ALS cases with a C9orf72 mutation (p&#xa0;&lt;&#xa0;0.0003). Blood neurofilament light protein discriminated better ALS from healthy controls (AUC: 0.92; p&#xa0;&lt;&#xa0;0.0001) and faster from slower progressing ALS (AUC: 0.86; p&#xa0;&lt;&#xa0;0.0001) compared to heavy-chain antibodies and light-chain immune complexes (AUC: 0.79; p&#xa0;&lt;&#xa0;0.0001 and AUC: 0.74; p&#xa0;&lt;&#xa0;0.0001). Lower neurofilament heavy antibodies were associated with longer survival (Log-rank Chi-square: 7.39; p&#xa0;=&#xa0;0.0065). Increasing levels of antibodies and immune complexes between time points were observed in faster progressing ALS.</AbstractText><AbstractText Label="CONCLUSIONS">We report a distinctive humoral response characterized by raising antibodies against neurofilaments and dipeptide repeats in faster progressing and C9orf72 genetic mutation carriers ALS patients. We confirm the significance of plasma neurofilament proteins in the clinical stratification of ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puentes</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3697-4726</Identifier><AffiliationInfo><Affiliation>Neurodegeneration Group, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurodegeneration Group, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ching-Hua</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, China Medical University, 91 Xueshi Road, North District, Taichung City, 404, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Neurodegeneration Group, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobeva</LastName><ForeName>Yoana</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neurodegeneration Group, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ALS Biomarker Consortium</CollectiveName><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CReATe Consortium</CollectiveName><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurodegeneration Group, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/M008606/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Office of Rare Diseases Research</Agency><Country/></Grant><Grant><GrantID>U54NS092091</GrantID><Agency>CReATe Consortium</Agency><Country/></Grant><Grant><Agency>Rare Diseases Clinical Research Network</Agency><Country/></Grant><Grant><GrantID>FRATTA/JAN15/946-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006508/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>17-CReATe-382</GrantID><Agency>ALS Association US</Agency><Country/></Grant><Grant><Agency>Motor Neuron Disease UK</Agency><Country/></Grant><Grant><GrantID>MALASPINA/APR13/817-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>H2020 PHC-13-2014</GrantID><Agency>EU2020</Agency><Country/></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>NCATS</Agency><Country/></Grant><Grant><Agency>NINDS</Agency><Country/></Grant><Grant><GrantID>MR/M015882/1</GrantID><Agency>MRC Industry Case Studentship</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>111365-29-8</RegistryNumber><NameOfSubstance UI="C061195">neurofilament protein M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="Y">Dipeptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="Y">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34318620</ArticleId><ArticleId IdType="pmc">PMC8419401</ArticleId><ArticleId IdType="doi">10.1002/acn3.51428</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Westeneng H&#x2010;J, Debray TPA, Visser AE, et&#xa0;al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, et&#xa0;al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population&#x2010;based cohort study. Lancet Neurol 2012;11:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Ilardi A, Cammarosano S, et&#xa0;al. Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology 2012;78:1085&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">22442427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Karlsson JE, Karlsson JO, et&#xa0;al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, et&#xa0;al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et&#xa0;al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22&#x2013;e30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre&#x2010;symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C&#x2010;H, Macdonald&#x2010;Wallis C, Gray E, et&#xa0;al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et&#xa0;al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 2020;95:e59&#x2013;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et&#xa0;al. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, et&#xa0;al. Association of regulatory T&#x2010;cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol 2018;75:681&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et&#xa0;al. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2017;2:e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol 1984;6:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredi M, Cavazzana I, Biasiotto G, et&#xa0;al. C9orf72 intermediate alleles in patients with amyotrophic lateral sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. Neuromolecular Med 2019;21:150&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">30859373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr Opin Neurol 2018;31:648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291817</ArticleId><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, et&#xa0;al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72&#x2010;associated amyotrophic lateral sclerosis. Sci Transl Med 2017;29:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RA, Gray E, Lu CH, et&#xa0;al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2015;2:748&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun N, Macklin EA, Sinani E, et&#xa0;al.; Pooled Resource Open&#x2010;Access ALSCTC . The revised El Escorial criteria "clinically probable laboratory supported ALS"&#x2010;once a promising now a superfluous category? Amyotroph Lateral Scler Frontotemporal Degener 2019;21:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31561715</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72&#x2010;mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 2018;14:544&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng S&#x2010;M, Arzberger T, et&#xa0;al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Topping J, Kuhle J, et&#xa0;al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2014;85:274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">24078718</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rol L, Lindner JM, Caudana P, et&#xa0;al. Loss of immune tolerance to IL&#x2010;2 in type 1 diabetes. Nat Commun 2016;7:13027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5059699</ArticleId><ArticleId IdType="pubmed">27708334</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Lu C&#x2010;H, Cho Y, et&#xa0;al. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J Neurochem 2018;146:631&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175430</ArticleId><ArticleId IdType="pubmed">29959860</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Poulter M, Lashley T, et&#xa0;al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol 2013;126:401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753468</ArticleId><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C&#x2010;H, Petzold A, Topping JO, et&#xa0;al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry 2015;86:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Petzold A, Kalmar B, et&#xa0;al. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One 2012;7:e40998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397981</ArticleId><ArticleId IdType="pubmed">22815892</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson MA, Banks WA. Age&#x2010;associated changes in the immune system and blood(&#x2010;)brain barrier functions. Int J Mol Sci 2019;20:1632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6479894</ArticleId><ArticleId IdType="pubmed">30986918</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova&#x2010;Davis S, Sanberg PR. Blood&#x2010;CNS barrier Impairment in ALS patients versus an animal model. Front Cell Neurosci 2014;8:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, van der Star BJ, Boomkamp SD, et&#xa0;al. Neurofilament light as an immune target for pathogenic antibodies. Immunology 2017;152:580&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5680069</ArticleId><ArticleId IdType="pubmed">28718500</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsinelos T, Tuck BJ, Mukadam AS, McEwan WA. The role of antibodies and their receptors in protection against ordered protein assembly in neurodegeneration. Front Immunol 2019;10:1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554282</ArticleId><ArticleId IdType="pubmed">31214163</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiutori R, Aarum J, Zubiri I, et&#xa0;al. The proteome of neurofilament&#x2010;containing protein aggregates in blood. Biochem Biophys Rep 2018;14:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986704</ArticleId><ArticleId IdType="pubmed">29872749</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, et&#xa0;al. Peripheral anti&#x2010;A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Folke J, Rydbirk R, Lokkegaard A, et&#xa0;al. Distinct autoimmune anti&#x2010;alpha&#x2010;synuclein antibody patterns in multiple system atrophy and Parkinson's disease. Front Immunol 2019;10:2253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769034</ArticleId><ArticleId IdType="pubmed">31616427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi V, Carassiti D, Giovannoni G, et&#xa0;al. Theme 7 pre&#x2010;clinical therapeutic strategies. Amyotroph Lateral Scler Frontotemporal Degener 2019;20(Sup1):217&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">31702471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>